Psyncretis
Business Services · Minnesota, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
701 Park Ave # Shapiro # S3111, Minneapo...Phone Number
(612) 347-4841Website
www.psyncretis.comRevenue
<$5 MillionIndustry
About Psyncretis
Psyncretis Org Chart
Is Psyncretis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Psyncretis launches new products
Click to see if Psyncretis had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Psyncretis
Funding: Get notified immidiatlly once Psyncretis has new funding data
Earning: See what the market has to say on Psyncretis recently announced quarterly report
Psyncretis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Psyncretis has recently received funding, and reach out quickly before it becomes old news!
Check out if Psyncretis is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Psyncretis
Find 2 more new buyers
Company Profile Activity
Activity Insights
Psyncretis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Psyncretis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Psyncretis.
Psyncretis Tech Stack
A closer look at the technologies used by Psyncretis
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Psyncretis
Psyncretis, Inc. is a privately owned company focused on the research and development of pharmaceuticals and biologics for nested markets, addressing biochemically-related diseases from orphan to large populations. The company's mission is to achieve parity in medicinal development for historically underserved and more prevalent patient populations... Read More